CLINICAL TRIALS Pancreatic Cancer About 84,000 people in the U.S. are living with pancreatic cancer, based on a 2018 estimate. In the U.S., only about 10% of patients live for at least 5 years after being diagnosed with pancreatic cancer, and about 48,000 patients were predicted to die of pancreatic cancer in 2021. Pancreatic cancer […]
PIPELINE CLINICAL TRIALS If you or a loved one are living with cancer, and you’re interested in learning about our clinical trials we currently have open, click below to learn more. < SEE OUR TRIALS >
OUR SCIENCE THE TARGET GSK-3β has long been an attractive target in cancer therapy, but previous drug candidates developed to inhibit GSK-3β have been limited by poor pharmaceutical characteristics and/or significant adverse effects in patients, limiting their clinical utility. The Function of GSK-3β GSK-3β is an enzyme that regulates a number of intersecting biological pathways
TIMELINE 2024 December 17, 2024 Positive Interim Phase 2 Data of Elraglusib in pancreatic cancer August 14, 2024 Initial Public Offering August 1, 2024 FDA Orphan Drug Designation for Elraglusib February 9, 2024 The Last Patient’s First Dose of Elraglusib in pancreatic cancer January 2024 Completion of Enrollment in Phase 2 clinical study in
ABOUT US Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41). Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such
THE PASSION TO PURSUE MORE Who we are Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting
PRIVACY NOTICE Last updated and effective as of December 20, 2023. This Privacy Notice explains the practices that Actuate Therapeutics, Inc. (“Actuate”, “we”, “us”, “our”) follows in connection with the personal data that we collect through this website, when you contact us directly and through our research. We may change this Privacy Notice at any
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate
